"name","rationale","description","instanceType","label","uuid:ID","id"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign","","f583e543-5465-4aa4-ab24-da4cc336461b","StudyDesign_1"
